Tipranavir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tipranavir: From HIV-1 Infection to Simian Immunodeficiency Virus Infection
One-Sentence Summary
Tipranavir is a non-peptidic protease inhibitor used in antiretroviral therapy for HIV-1 infection. The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, with a very high prediction score but no clinical trials or published literature currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (pharmacological classification; TFDA-approved indication text not available in this evidence pack) |
| Predicted New Indication | Simian Immunodeficiency Virus Infection |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on general pharmacological classification, tipranavir belongs to the HIV protease inhibitor class, and its efficacy in HIV-1 infection is well established in treatment-experienced patients.
Simian Immunodeficiency Virus (SIV) is a lentivirus closely related to HIV-1, sharing significant structural homology in its viral protease enzyme. This phylogenetic and structural similarity is the most plausible mechanistic basis for the TxGNN model linking a human HIV protease inhibitor to an SIV indication — the knowledge graph likely captured shared “lentivirus / protease inhibitor” relationships rather than any direct clinical evidence.
However, it is important to note that SIV infection is a veterinary/primate model disease, not a human clinical indication. Even if mechanistically plausible, there is currently zero clinical trial or literature evidence directly supporting this specific prediction, and no established regulatory pathway exists for repurposing a human antiretroviral into this indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA label warnings/contraindications are currently a Blocking data gap (DG001) — this evidence pack cannot support a full safety (S1) assessment until this data is obtained.
Additional Context: Other Candidate Indications
Beyond the top-ranked prediction, this evidence pack includes 9 additional candidate indications for tipranavir. Most were internally flagged as likely false positives (evidence level L5, decision stage S0, recommendation Hold) due to lack of biological plausibility with protease-inhibitor pharmacology — e.g., fibroma of prostate, Brenner tumor, and a rare neurodevelopmental disorder, none of which have any supporting evidence.
One candidate worth noting separately is rank 5, “congenital human immunodeficiency virus” (score 99.83%), which is linked to 9 Phase 2/3 clinical trials on HIV-1 antiretroviral regimens. However, these trials concern general adult HIV-1 virologic suppression, not specifically congenital/perinatal transmission, and their relevance grading is still marked “pending” — this candidate may warrant follow-up evidence review before the top-ranked SIV prediction.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (SIV infection) has no clinical trial or literature support and targets a non-human disease model with no clear human repurposing pathway. Combined with a Blocking data gap on TFDA safety labeling and the drug’s current non-marketed status in this jurisdiction, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA package insert data (warnings, contraindications) — currently blocking (DG001)
- Confirmed mechanism of action (MOA) detail from DrugBank (DG002)
- Clarification of clinical relevance/translatability of the SIV-infection signal to any human indication
- Relevance grading and follow-up evidence review for the “congenital HIV” candidate (rank 5), which has the strongest existing trial base among all listed candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.